alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
II 

115TH CONGRESS 

1ST SESSION S. 1039 

To indemnify local law enforcement entities for complying with valid detainers 

issued by immigration officers. 

IN THE SENATE OF THE UNITED STATES 

MAY 4, 2017 

Mr. FLAKE (for himself and Mr. MCCAIN) introduced the following bill; which 

was read twice and referred to the Committee on the Judiciary 

A BILL 

To indemnify local law enforcement entities for complying 

with valid detainers issued by immigration officers. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. STATEMENT OF PURPOSE. 

4 The purpose of this Act is to ensure that States and 

5 localities do not incur costs by complying in good faith 

6 with immigration detainers issued by the Federal Govern7 ment. 

8 SEC. 2. FEDERAL GOVERNMENT COSTS. 

9 Since immigration detainers are issued by Federal of10 ficials based upon information about an alien’s immigraVerDate Sep 11 2014 18:31 May 10, 2017 Jkt 069200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\S1039.IS S1039

sradovich on DSK3GMQ082PROD with BILLS
2 

•S 1039 IS

1 tion status that is often only known by such officials, the 

2 Federal Government shall be responsible to pay for the 

3 costs of any legally cognizable injuries to third parties re4 sulting from the issuance and execution of such detainers. 

5 SEC. 3. INDEMNIFICATION FOR LOCAL LAW ENFORCE6 MENT. 

7 Section 287 of the Immigration and Nationality Act 

8 (8 U.S.C. 1357) is amended by adding at the end the fol9 lowing: 

10 ‘‘(i) Subject to available appropriations, a State or 

11 its employee, a political subdivision of a State or its em12 ployee, or an elected official that receives a request from 

13 U.S. Immigration and Customs Enforcement to tempo14 rarily detain an alien or transport the alien to a Federal 

15 detention center shall be indemnified and held harmless 

16 by the Secretary of Homeland Security from all claims by 

17 any person that may arise from good faith compliance with 

18 such request.’’. 

19 SEC. 4. SAVINGS PROVISION. 

20 Nothing in this Act may be construed to preclude a 

21 legal cause of action. 

Æ 


sradovich on DSK3GMQ082PROD with BILLS
109TH CONGRESS

1ST SESSION S. 1095

AN ACT

To amend chapter 113 of title 18, United States Code,

to clarify the prohibition on the trafficking in goods

or services, and for other purposes.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,
 †

2

S 1095 ES

1 SECTION 1. TRAFFICKING DEFINED.

2 (a) COUNTERFEIT GOODS OR SERVICES.—Section

3 2320(e) of title 18, United States Code, is amended—

4 (1) by striking paragraph (2) and inserting the

5 following:

6 ‘‘(2) the term ‘traffic’ means to transport,

7 transfer, or otherwise dispose of, to another, for pur8 poses of commercial advantage or private financial

9 gain, or to make, import, export, obtain control of,

10 or possess, with intent to so transport, transfer, or

11 otherwise dispose of;’’; and

12 (2) by redesignating paragraph (3) as para13 graph (4) and inserting the following:

14 ‘‘(3) the term ‘financial gain’ includes the re15 ceipt, or expected receipt, of anything of value;

16 and’’.

17 (b) CONFORMING AMENDMENTS.—

18 (1) SOUND RECORDINGS AND MUSIC VIDEOS OF

19 LIVE MUSICAL PERFORMANCES.—Section 2319A(e)

20 of title 18, United States Code, is amended by strik21 ing paragraph (2) and inserting the following:

22 ‘‘(2) the term ‘traffic’ has the same meaning as

23 in section 2320(e) of this title.’’.

24 (2) COUNTERFEIT LABELS FOR

25 PHONORECORDS, COMPUTER PROGRAMS, ETC.—Sec26 tion 2318(b) of title 18, United States Code, is
†

3

S 1095 ES

1 amended by striking paragraph (2) and inserting the

2 following:

3 ‘‘(2) the term ‘traffic’ has the same meaning as

4 in section 2320(e) of this title;’’.

5 (3) ANTI-BOOTLEGGING.—Section 1101 of title

6 17, United States Code, is amended by striking sub7 section (b) and inserting the following:

8 ‘‘(b) DEFINITION.—As used in this section, the term

9 ‘traffic’ has the same meaning as in section 2320(e) of

10 title 18, United States Code.’’.

Passed the Senate November 10, 2005.

Attest:

Secretary.
109TH CONGRESS

1ST SESSION S. 1095

AN ACT

To amend chapter 113 of title 18, United States

in goods or services, and for other purposes.Code, to clarify the prohibition on the trafficking
#### § 206.3 Definitions.

The following definitions apply to this part:

*The act* means the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 *et seq.*).

*Debossed* means imprinted with a mark below the dosage form surface.

*Drug product* means a finished dosage form, e.g., a tablet or capsule that contains a drug substance, generally, but not necessarily, in association with one or more other ingredients.

*Embossed* means imprinted with a mark raised above the dosage form surface.

*Engraved* means imprinted with a code that is cut into the dosage form surface after it has been completed.

*Imprinted* means marked with an identification code by means of embossing, debossing, engraving, or printing with ink.

*Manufacturer* means the manufacturer as described in §§ 201.1 and 600.3(t) of this chapter.

*Solid oral dosage form* means capsules, tablets, or similar drug products intended for oral use.
§ 203.22 Exclusions. Section 203.20 does not apply to: ( a ) The purchase or other acquisition of a drug for its own use by a hospital or other health care entity that is a member of a group purchasing organization from the group purchasing organization or from other hospitals or health care entities that are members of the organization.
( b ) The sale, purchase, or trade of a drug or an offer to sell, purchase, or trade a drug by a charitable organization to a nonprofit affiliate of the organization to the extent otherwise permitted by law.
( c ) The sale, purchase, or trade of a drug or an offer to sell, purchase, or trade a drug among hospitals or other health care entities that are under common control.
( d ) The sale, purchase, or trade of a drug or an offer to sell, purchase, or trade a drug for emergency medical reasons.
( e ) The sale, purchase, or trade of a drug, an offer to sell, purchase, or trade a drug, or the dispensing of a drug under a valid prescription.
( f ) The sale, purchase, or trade of a drug or the offer to sell, purchase, or trade a drug by hospitals or health care entities owned or operated by Federal, State, or local governmental units to other hospitals or health care entities owned or operated by Federal, State, or local governmental units.
( g ) The sale, purchase, or trade of, or the offer to sell, purchase, or trade blood or blood components intended for transfusion.
( h ) The sale, purchase, or trade of, or the offer to sell, purchase, or trade, by a registered blood establishment that qualifies as a health care entity any: ( 1 ) Drug indicated for a bleeding or clotting disorder, or anemia;
( 2 ) Blood collection container approved under section 505 of the act; or
( 3 ) Drug that is a blood derivative (or a recombinant or synthetic form of a blood derivative); as long as all of the health care services that the establishment provides are related to its activities as a registered blood establishment or the health care services consist of collecting, processing, storing, or administering human hematopoietic stem/progenitor cells or performing diagnostic testing of specimens provided that these specimens are tested together with specimens undergoing routine donor testing. Blood establishments relying on the exclusion in this paragraph must satisfy all other requirements of the act and this part applicable to a wholesale distributor or retail pharmacy.
( i ) The sale, purchase, or trade of, or the offer to sell, purchase, or trade, by a comprehensive hemophilia diagnostic treatment center that is receiving a grant under section 501(a)(2) of the Social Security Act and that qualifies as a health care entity, any drug indicated for a bleeding or clotting disorder, or anemia, or any drug that is a blood derivative (or a recombinant or synthetic form of a blood derivative). Comprehensive hemophilia diagnostic treatment centers relying on the exclusion in this paragraph must satisfy all other requirements of the act and this part applicable to a wholesale distributor or retail pharmacy.
[64 FR 67756, Dec. 3, 1999, as amended at 73 FR 59500, Oct. 9, 2008]
CERTIFICATION
      (e)
    
    Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which
this report is being prepared;(f)
    
    Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;(g)
    
    Evaluated the effectiveness of the registrants disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report
based on such evaluation; and(h)
    
    Disclosed in this report any change in the registrants internal control over
financial reporting that occurred during the registrants most recent fiscal quarter
(the registrants fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrants
internal control over financial reporting; and
  (c)
    
    All significant deficiencies and material weaknesses in the design or operation
of internal control over financial reporting which are reasonably likely to adversely
affect the registrants ability to record, process, summarize and report financial
information; and(d)
    
    Any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrants internal control over financial
reporting.
  /s/ Uzi Sasson

Uzi Sasson, President and Chief Financial Officer
IV 

House Calendar No. 5 

115TH CONGRESS 

1ST SESSION H. RES. 55 

[Report No. 115–5] 

Providing for consideration of the bill (H.R. 7) to prohibit taxpayer funded 

abortions. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 23, 2017 

Ms. CHENEY, from the Committee on Rules, reported the following resolution; 

which was referred to the House Calendar and ordered to be printed 

RESOLUTION 

Providing for consideration of the bill (H.R. 7) to prohibit 

taxpayer funded abortions. 

1 Resolved, That upon adoption of this resolution it 

2 shall be in order to consider in the House the bill (H.R. 

3 7) to prohibit taxpayer funded abortions. All points of 

4 order against consideration of the bill are waived. The bill 

5 shall be considered as read. All points of order against 

6 provisions in the bill are waived. The previous question 

7 shall be considered as ordered on the bill and on any 

8 amendment thereto to final passage without intervening 


sradovich on DSK3GMQ082PROD with BILLS
2 

•HRES 55 RH 

1 motion except: (1) one hour of debate equally divided and 

2 controlled by the Majority Leader and the Minority Lead3 er or their respective designees; and (2) one motion to re4 commit. 


sradovich on DSK3GMQ082PROD with BILLS

sradovich on DSK3GMQ082PROD with BILLS
House Calendar No. 5 

115TH CONGRESS 

1ST SESSION H. RES. 55 

[Report No. 115–5] 

RESOLUTION 

Providing for consideration of the bill (H.R. 7) to 

prohibit taxpayer funded abortions. 

JANUARY 23, 2017 

Referred to the House Calendar and ordered to be 

printed 


sradovich on DSK3GMQ082PROD with BILLS
## In The

Court of Appeals

Sixth Appellate District of Texas at Texarkana

No. 06

- 19

- 00003

- CV

IN THE INTEREST OF A.S., A CHILD

On Appeal from the 62nd District Court

Delta County, Texas

Trial Court No. 11100

Before Morriss, C.J., Burgess and Stevens, JJ.

Memorandum Opinion by Chief Justice Morriss2 

### MEMORANDUM OPINION

The appellant ha s filed a motion with this Court seeking to voluntarily dismiss t h is appeal.

Pursuant to Rule 42.1(a)(1) of the Texas Rules of Appellate Procedure, the motion is granted. See

T EX

. R. A PP

. P. 42.1(a)(1). Accordingly, we dismiss this appeal

.

Josh R. Morriss, III

Chief Justice

Date Submitted: March 18, 2019

Date Decided: March 19, 2019
Exhibit 32.1



CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350)



The undersigned, R. Brad Martin, Chairman of the Board of Directors and Chief Executive Officer of Saks Incorporated (the Company), has
executed this certification in connection with the filing with the Securities and Exchange Commission of the Companys Quarterly Report on Form 10-Q for the quarter ended October 29, 2005 (the Report).



The undersigned hereby certifies that:



| | 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | -- | ---------------------------------------------------------------------------------------------------------------------



| | 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------



IN WITNESS WHEREOF, the undersigned has executed this
certification as of the 8th day of December 2005.



|                                                              
|--------------------------------------------------------------
|/s/ R. Brad Martin                                            
|R. Brad Martin                                                
|Chairman of the Board of Directors and Chief Executive Officer



A signed original of this written
statement required by Section 906 has been provided to Saks Incorporated and will be retained by Saks Incorporated and furnished to the Securities and Exchange Commission or its staff upon request.
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.127 Drugs; expiration of exemptions. ( a ) If a shipment or delivery, or any part thereof, of a drug which is exempt under the regulations in this section is made to a person in whose possession the article is not exempt, or is made for any purpose other than those specified, such exemption shall expire, with respect to such shipment or delivery or part thereof, at the beginning of that shipment or delivery. The causing of an exemption to expire shall be considered an act which results in such drug being misbranded unless it is disposed of under circumstances in which it ceases to be a drug or device.
( b ) The exemptions conferred by §§ 201.117, 201.119, 201.120, 201.122, and 201.125 shall continue until the drugs are used for the purposes for which they are exempted, or until they are relabeled to comply with section 502(f)(1) of the act. If, however, the drug is converted, compounded, or manufactured into a dosage form limited to prescription dispensing, no exemption shall thereafter apply to the article unless the dosage form is labeled as required by section 503(b) and §§ 201.100 or 201.105.
[41 FR 6911, Feb. 13, 1976]
Exhibit 32.1



CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In  connection  with the  annual  report of  NatureWell, Incorporated (the "Company")  on Form 10-KSB for the period ended June 30, 2004 as filed with the Securities  and  Exchange  Commission  on the date  hereof  (the  "Report")  the undersigned  hereby  certifies  pursuant to 18 U.S.C.  Section  1350, as adopted pursuant to Section 906 of the  Sarbanes-Oxley  Act of 2002, that to the best of my knowledge:



|(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                                        
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                              
|(2) | The  information  contained in the Report fairly  presents,  in all material  respects,  the  financial  condition  and results of operations of the Company.



|Dated: October 13, 2004 | /s/ JAMES R. ARABIA                    
|----------------------- | ---------------------------------------
|                        |                                        
|                        | James R. Arabia
Chief Executive Officer
<TABLE> <S> <C>

<ARTICLE> 9
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
REGISTRANT'S FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 1997 AND
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                          18,561
<INT-BEARING-DEPOSITS>                               0
<FED-FUNDS-SOLD>                                20,250
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                      1,760
<INVESTMENTS-CARRYING>                          48,931
<INVESTMENTS-MARKET>                            48,550
<LOANS>                                        205,703
<ALLOWANCE>                                      3,198
<TOTAL-ASSETS>                                 300,315
<DEPOSITS>                                     270,080
<SHORT-TERM>                                     1,000
<LIABILITIES-OTHER>                              1,386
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           711
<OTHER-SE>                                      27,138
<TOTAL-LIABILITIES-AND-EQUITY>                 300,315
<INTEREST-LOAN>                                  4,597
<INTEREST-INVEST>                                  731
<INTEREST-OTHER>                                     0
<INTEREST-TOTAL>                                 5,585
<INTEREST-DEPOSIT>                               1,647
<INTEREST-EXPENSE>                               1,657
<INTEREST-INCOME-NET>                            3,928
<LOAN-LOSSES>                                      180
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                  4,245
<INCOME-PRETAX>                                    258
<INCOME-PRE-EXTRAORDINARY>                         158
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       158
<EPS-PRIMARY>                                      .22
<EPS-DILUTED>                                      .22
<YIELD-ACTUAL>                                    5.84
<LOANS-NON>                                      3,458
<LOANS-PAST>                                       595
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                 3,067
<CHARGE-OFFS>                                       60
<RECOVERIES>                                        11
<ALLOWANCE-CLOSE>                                3,198
<ALLOWANCE-DOMESTIC>                             3,198
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                            620
        

</TABLE>
# C_2019250EN.01000101.xml

| 25.7.2019 | EN | Official Journal of the European Union | C 250/1 |
| --- | --- | --- | --- |

25.7.2019

EN

Official Journal of the European Union

C 250/1

---

Joint Statement by the Parliament, the Council and the Commission relating to Regulation (EU) 2019/1243 of the European Parliament and of the Council of 20 June 2019 adapting a number of legal acts providing for the use of the regulatory procedure with scrutiny to Articles 290 and 291 of the Treaty on the Functioning of the European Union (1)

(2019/C 250/01)

In point 27 of the Interinstitutional Agreement on Better Law-Making the three institutions acknowledged the need for the alignment of all existing legislation to the legal framework introduced by the Lisbon Treaty, and in particular the need to give high priority to the prompt alignment of all basic acts which still refer to the regulatory procedure with scrutiny. Following the proposal of the Commission to that end, this Regulation responds to that need by providing for the alignment of the regulatory procedure with scrutiny in a significant number of acts included in that proposal. The three institutions will continue to work on the alignment of the remaining acts of that proposal.

---

(1)  OJ L 198, 25.7.2019, p. 241.

---
§ 139.121 Nonfat milk macaroni products. ( a ) Each of the macaroni products made with nonfat milk for which a definition and standard of identity is prescribed by this section conforms to the definition and standard of identity, and is subject to the requirements for label statement of ingredients, prescribed for macaroni products by § 139.110(a), (f)(2), (f)(3), (f)(4), and (g), except that: ( 1 ) ( i ) In preparing the dough, nonfat dry milk or concentrated skim milk, or a mixture of these, is used in an amount such that the finished macaroni product made with nonfat milk contains by weight not less than 12 percent and not more than 25 percent of milk solids-not-fat. Carrageenan or salts of carrageenan conforming to the requirements of §§ 172.620 and 172.626 of this chapter may be used in a quantity not in excess of 0.833 percent by weight of the milk solids-not-fat used.
( ii ) When the ingredient carrageenan or the salts of carrageenan specified in paragraph (a)(1)(i) of this section is used, the label shall bear the statement, “Carrageenan added” or “Salts of carrageenan added” or the statement “With added carrageenan” or “With added salts of carrageenan”, in the manner further prescribed by § 139.110(f)(4).
( 2 ) None of the optional ingredients permitted by § 139.110(a) (1), (2), and (5) are used.
( b ) The name of each food for which a definition and standard of identity is prescribed by this section is “Macaroni products made with nonfat milk” or, alternatively, the name is “Macaroni made with nonfat milk”, “Spaghetti made with nonfat milk” or “Vermicelli made with nonfat milk”, as the case may be when the units of the food conform to the specifications of shape and size prescribed by § 139.110 (b), (c), or (d), respectively.
[42 FR 14409, Mar. 15, 1977, as amended at 58 FR 2878, Jan. 6, 1993]